Protocol Ledger

NCT06997588 · Phase II · RECRUITING

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Interventional Phase II clinical trial protocol NCT06997588 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-09 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06997588
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06997588
Protocol FieldVerified Registry Value
NCT IdentifierNCT06997588
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2025-10-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI